DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Completed

Conditions: Hereditary Angioedema (HAE)
Angioedema

Interventions: Other: No Intervention

First Posted Date: 2022-10-13

Last Posted Date: 2024-07-30

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT05578417

Locations: 🇨🇦
CHU de Québec - Université Laval, Quebec, Canada
🇨🇦
Hamilton Health Science Corporation, Hamilton, Ontario, Canada
🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada

and more 2 locations

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

Completed

Conditions: Cytomegalovirus (CMV)

First Posted Date: 2022-10-07

Last Posted Date: 2024-02-28

Lead Sponsor: Takeda

Target Recruit Count: 118

Registration Number: NCT05571137

Locations: 🇦🇹
MU Graz, Graz, Austria
🇧🇪
UZ Leuven, Leuven, Belgium
🇷🇸
Clinical Center of Vojvodina, Novi Sad, Serbia

and more 8 locations

A Study of TAK-951 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-951
Drug: TAK-951 Placebo

First Posted Date: 2022-10-05

Last Posted Date: 2023-09-14

Lead Sponsor: Takeda

Target Recruit Count: 128

Registration Number: NCT05567393

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX

Recruiting

Conditions: Short Bowel Syndrome (SBS)

Interventions: Other: No Intervention

First Posted Date: 2022-09-30

Last Posted Date: 2024-12-04

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT05561647

Locations: 🇺🇸
Shire-NPS Pharmaceuticals, INC., Lexington, Massachusetts, United States

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp alfa
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Bortezomib
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2022-09-27

Last Posted Date: 2024-12-24

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05556616

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Scripps Health, San Diego, California, United States

and more 18 locations

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase 3

Active, not recruiting

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)

Interventions: Drug: TAK-625

First Posted Date: 2022-09-16

Last Posted Date: 2023-11-07

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT05543187

Locations: 🇯🇵
Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan

and more 5 locations

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Phase 3

Active, not recruiting

Conditions: Alagille Syndrome (ALGS)

Interventions: Drug: TAK-625

First Posted Date: 2022-09-16

Last Posted Date: 2024-10-11

Lead Sponsor: Takeda

Target Recruit Count: 7

Registration Number: NCT05543174

Locations: 🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
🇯🇵
Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Osaka University Hospital, Suita, Osaka, Japan

and more 5 locations

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Velaglucerase Alfa

First Posted Date: 2022-09-07

Last Posted Date: 2025-02-26

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT05529992

Locations: 🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China

and more 7 locations

A Study of TAK-341 in Treatment of Multiple System Atrophy

Phase 2

Active, not recruiting

Conditions: Multiple System Atrophy

Interventions: Drug: TAK-341
Drug: Placebo

First Posted Date: 2022-09-02

Last Posted Date: 2024-08-01

Lead Sponsor: Takeda

Target Recruit Count: 159

Registration Number: NCT05526391

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 38 locations

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Phase 3

Active, not recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Drug: TAK-771

First Posted Date: 2022-08-24

Last Posted Date: 2025-05-11

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05513586

Locations: 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy